Mutationen und Polymorphismen im β-MHC- und Troponin T-Gen bei Patienten mit dilatativer KardiomyopathieSteffen DähmlowMeinen Eltern11.111.21.31.421.51.63548#5821.6.11.6.24416#3065671.6.31.6.481.6.51.79292.1102.22.2.12.2.22.32.3.1112.3.2122.3.313142.3.4152.3.516172.3.62.3.7181919202.3.8212.3.9222.42.4.12.4.2232.4.3243243.1253.226617#2613.2.13.2.1.127558#238597#187283.2.1.2445#23829622#1873.2.1.330557#4733.2.23.2.2.131133#2393.2.2.2492#2383.2.33.2.3.132606#201606#248333.2.3.2606#20134606#2393.2.3.3322#19135606#2483.2.3.436606#2483.2.3.5606#24837558#2013.2.3.638606#2483.2.4393.34041614#2363.3.13.3.1.1568#19242606#2483.3.1.243124#192606#2483.3.1.344606#2483.3.1.445606#20146606#2483.3.1.5124#19247606#2483.3.1.648606#248568#2013.3.249504504.1514.2524.3534.44.5544.6554.7555LiteraturAbkürzungenDanksagungLebenslaufPublikationenEidesstattliche ErklärungdeInhaltsverzeichnisHilfe Literatur [1] Brigden, W. (1957): Uncommon myocardial diseases: the non-coronary cardiomyopathies, Lancet (2), Seite 1179-84. [2] Goodwin, J. F. und Oakley, C. M. (1972): The cardiomyopathies, Br Heart J (34) [6], Seite 545-52. [3] (1980): Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies, Br Heart J (44) [6], Seite 672-3. [4] Richardson, P.; McKenna, W.; Bristow, M.; Maisch, B.; Mautner, B.; O'Connell, J.; Olsen, E.; Thiene, G.; Goodwin, J.; Gyarfas, I.; Martin, I. und Nordet, P. (1996): Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies, Circulation (93) [5], Seite 841-2. [5] Felker, G. M.; Thompson, R. E.; Hare, J. M.; Hruban, R. H.; Clemetson, D. E.; Howard, D. L.; Baughman, K. L. und Kasper, E. K. (2000): Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy, N Engl J Med (342) [15], Seite 1077-84. [6] Codd, M. B.; Sugrue, D. D.; Gersh, B. J. und Melton, L. J., 3rd (1989): Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984, Circulation (80) [3], Seite 564-72. [7] Rakar, S.; Sinagra, G.; Di Lenarda, A.; Poletti, A.; Bussani, R.; Silvestri, F. und Camerini, F. (1997): Epidemiology of dilated cardiomyopathy. A prospective post-mortem study of 5252 necropsies. The Heart Muscle Disease Study Group, Eur Heart J (18) [1], Seite 117-23. [8] Komajda, M.; Jais, J. P.; Reeves, F.; Goldfarb, B.; Bouhour, J. B.; Juillieres, Y.; Lanfranchi, J.; Peycelon, P.; Geslin, P.; Carrie, D. und et al. (1990): Factors predicting mortality in idiopathic dilated cardiomyopathy, Eur Heart J (11) [9], Seite 824-31. [9] Sugrue, D. D.; Rodeheffer, R. J.; Codd, M. B.; Ballard, D. J.; Fuster, V. und Gersh, B. J. (1992): The clinical course of idiopathic dilated cardiomyopathy. A population-based study, Ann Intern Med (117) [2], Seite 117-23. [10] Johnson, R. A. und Palacios, I. (1982): Dilated cardiomyopathies of the adult (first of two parts), N Engl J Med (307) [17], Seite 1051-8. [11] Aretz, H. T. (1987): Myocarditis: the Dallas criteria, Hum Pathol (18) [6], Seite 619-24. [12] Maisch, B.; Portig, I.; Ristic, A.; Hufnagel, G. und Pankuweit, S. (2000): Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. A status report, Herz (25) [3], Seite 200-9. [13] Hoppe, U. C.; Bohm, M.; Dietz, R.; Hanrath, P.; Kroemer, H. K.; Osterspey, A.; Schmaltz, A. A. und Erdmann, E. (2005): Leitlinien zur Therapie der chronischen Herzinsuffizienz, Z Kardiol (94) [8], Seite 488-509. [14] Swedberg, K.; Cleland, J.; Dargie, H.; Drexler, H.; Follath, F.; Komajda, M.; Tavazzi, L.; Smiseth, O. A.; Gavazzi, A.; Haverich, A.; Hoes, A.; Jaarsma, T.; Korewicki, J.; Levy, S.; Linde, C.; Lopez-Sendon, J. L.; Nieminen, M. S.; Pierard, L. und Remme, W. J. (2005): Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology, Eur Heart J (26) [11], Seite 1115-40. Epub 2005 May 18. [15] Battersby, E.J. und Glenner, G.G. (1961): Familial cardiomyopathy, Am J Med (30), Seite 382-91. [16] Schrader, W.H.; Pankey, G.A.; Davis, R.B. und Theologides, A. (1961): Familial idiopathic cardiomegaly, Circulation (24), Seite 599-606. [17] Whitfield, A.G. (1961): Familial cardiomyopathy, Quart J Med (3), Seite 119-34. [18] Mestroni, L.; Maisch, B.; McKenna, W. J.; Schwartz, K.; Charron, P.; Rocco, C.; Tesson, F.; Richter, A.; Wilke, A. und Komajda, M. (1999): Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy, Eur Heart J (20) [2], Seite 93-102. [19] Michels, V. V.; Moll, P. P.; Miller, F. A.; Tajik, A. J.; Chu, J. S.; Driscoll, D. J.; Burnett, J. C.; Rodeheffer, R. J.; Chesebro, J. H. und Tazelaar, H. D. (1992): The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy, N Engl J Med (326) [2], Seite 77-82. [20] Grünig, E.; Tasman, J. A.; Kucherer, H.; Franz, W.; Kubler, W. und Katus, H. A. (1998): Frequency and phenotypes of familial dilated cardiomyopathy, J Am Coll Cardiol (31) [1], Seite 186-94. [21] Mestroni, L.; Rocco, C.; Gregori, D.; Sinagra, G.; Di Lenarda, A.; Miocic, S.; Vatta, M.; Pinamonti, B.; Muntoni, F.; Caforio, A. L.; McKenna, W. J.; Falaschi, A.; Giacca, M. und Camerini (1999): Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group, J Am Coll Cardiol (34) [1], Seite 181-90. [22] Kelly, D. P. und Strauss, A. W. (1994): Inherited cardiomyopathies, N Engl J Med (330) [13], Seite 913-9. [23] Suomalainen, A.; Paetau, A.; Leinonen, H.; Majander, A.; Peltonen, L. und Somer, H. (1992): Inherited idiopathic dilated cardiomyopathy with multiple deletions of mitochondrial DNA, Lancet (340) [8831], Seite 1319-20. [24] Zeviani, M.; Servidei, S.; Gellera, C.; Bertini, E.; DiMauro, S. und DiDonato, S. (1989): An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region, Nature (339) [6222], Seite 309-11. [25] Bowles, N. E.; Bowles, K. R. und Towbin, J. A. (2000): The "final common pathway" hypothesis and inherited cardiovascular disease. The role of cytoskeletal proteins in dilated cardiomyopathy, Herz (25) [3], Seite 168-75. [26] Jung, M.; Poepping, I.; Perrot, A.; Ellmer, A. E.; Wienker, T. F.; Dietz, R.; Reis, A. und Osterziel, K. J. (1999): Investigation of a family with autosomal dominant dilated cardiomyopathy defines a novel locus on chromosome 2q14-q22, Am J Hum Genet (65) [4], Seite 1068-77. [27] Sylvius, N.; Tesson, F.; Gayet, C.; Charron, P.; Benaiche, A.; Peuchmaurd, M.; Duboscq-Bidot, L.; Feingold, J.; Beckmann, J. S.; Bouchier, C. und Komajda, M. (2001): A new locus for autosomal dominant dilated cardiomyopathy identified on chromosome 6q12-q16, Am J Hum Genet (68) [1], Seite 241-6. [28] Messina, D. N.; Speer, M. C.; Pericak-Vance, M. A. und McNally, E. M. (1997): Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23, Am J Hum Genet (61) [4], Seite 909-17. [29] Krajinovic, M.; Pinamonti, B.; Sinagra, G.; Vatta, M.; Severini, G. M.; Milasin, J.; Falaschi, A.; Camerini, F.; Giacca, M. und Mestroni, L. (1995): Linkage of familial dilated cardiomyopathy to chromosome 9. Heart Muscle Disease Study Group, Am J Hum Genet (57) [4], Seite 846-52. [30] Bowles, K. R.; Gajarski, R.; Porter, P.; Goytia, V.; Bachinski, L.; Roberts, R.; Pignatelli, R. und Towbin, J. A. (1996): Gene mapping of familial autosomal dominant dilated cardiomyopathy to chromosome 10q21-23, J Clin Invest (98) [6], Seite 1355-60. [31] Osterziel, K. J. und Perrot, A. (2005): Dilated cardiomyopathy: more genes means more phenotypes, Eur Heart J (21), Seite 21 [32] Muntoni, F.; Cau, M.; Ganau, A.; Congiu, R.; Arvedi, G.; Mateddu, A.; Marrosu, M. G.; Cianchetti, C.; Realdi, G.; Cao, A. und et al. (1993): Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy, N Engl J Med (329) [13], Seite 921-5. [33] Hoffman, E. P.; Brown, R. H., Jr. und Kunkel, L. M. (1987): Dystrophin: the protein product of the Duchenne muscular dystrophy locus, Cell (51) [6], Seite 919-28. [34] Tsubata, S.; Bowles, K. R.; Vatta, M.; Zintz, C.; Titus, J.; Muhonen, L.; Bowles, N. E. und Towbin, J. A. (2000): Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy, J Clin Invest (106) [5], Seite 655-62. [35] Li, D.; Tapscoft, T.; Gonzalez, O.; Burch, P. E.; Quinones, M. A.; Zoghbi, W. A.; Hill, R.; Bachinski, L. L.; Mann, D. L. und Roberts, R. (1999): Desmin mutation responsible for idiopathic dilated cardiomyopathy, Circulation (100) [5], Seite 461-4. [36] Kass, S.; MacRae, C.; Graber, H. L.; Sparks, E. A.; McNamara, D.; Boudoulas, H.; Basson, C. T.; Baker, P. B., 3rd; Cody, R. J. und andere (1994): A gene defect that causes conduction system disease and dilated cardiomyopathy maps to chromosome 1p1-1q1, Nat Genet (7) [4], Seite 546-51. [37] Fatkin, D.; MacRae, C.; Sasaki, T.; Wolff, M. R.; Porcu, M.; Frenneaux, M.; Atherton, J.; Vidaillet, H. J., Jr.; Spudich, S.; De Girolami, U.; Seidman, J. G.; Seidman, C.; Muntoni, F.; Muehle, G.; Johnson, W. und McDonough, B. (1999): Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease, N Engl J Med (341) [23], Seite 1715-24. [38] Olson, T. M.; Michels, V. V.; Thibodeau, S. N.; Tai, Y. S. und Keating, M. T. (1998): Actin mutations in dilated cardiomyopathy, a heritable form of heart failure, Science (280) [5364], Seite 750-2. [39] Seidman, J. G. und Seidman, C. (2001): The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms, Cell (104) [4], Seite 557-67. [40] Royal Prince Alfred Hospital Sydney, Australien:: FHC mutation database. http://www.angis.org.au/Databases/Heart/ Stand: 15. März 2005. [41] University of Wales College of Medicine, UK:: Human Gene Mutation Database at the Institute of Medical Genetics. http://archive.uwcm.ac.uk/uwcm/mg/hgmd0.html". Stand: 15. März 2005. [42] CardioGenomics Program for Genomic Applications Project 3 Boston, USA:: Mutation database. http://genetics.med.harvard.edu/~seidman/cg3". Stand: 15. März 2005. [43] Satoh, M.; Takahashi, M.; Sakamoto, T.; Hiroe, M.; Marumo, F. und Kimura, A. (1999): Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene, Biochem Biophys Res Commun (262) [2], Seite 411-7. [44] Blair, E.; Redwood, C.; Ashrafian, H.; Oliveira, M.; Broxholme, J.; Kerr, B.; Salmon, A.; Ostman-Smith, I. und Watkins, H. (2001): Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis, Hum Mol Genet (10) [11], Seite 1215-20. [45] Geier, C.; Perrot, A.; Ozcelik, C.; Binner, P.; Counsell, D.; Hoffmann, K.; Pilz, B.; Martiniak, Y.; Gehmlich, K.; van der Ven, P. F.; Furst, D. O.; Vornwald, A.; von Hodenberg, E.; Nurnberg, P.; Scheffold, T.; Dietz, R. und Osterziel, K. J. (2003): Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy, Circulation (107) [10], Seite 1390-5. [46] Hayashi, T.; Arimura, T.; Itoh-Satoh, M.; Ueda, K.; Hohda, S.; Inagaki, N.; Takahashi, M.; Hori, H.; Yasunami, M.; Nishi, H.; Koga, Y.; Nakamura, H.; Matsuzaki, M.; Choi, B. Y.; Bae, S. W.; You, C. W.; Han, K. H.; Park, J. E.; Knoll, R.; Hoshijima, M.; Chien, K. R. und Kimura, A. (2004): Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy, J Am Coll Cardiol (44) [11], Seite 2192-201. [47] Thierfelder, L.; Watkins, H.; MacRae, C.; Lamas, R.; McKenna, W.; Vosberg, H. P.; Seidman, J. G. und Seidman, C. E. (1994): Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere, Cell (77) [5], Seite 701-12. [48] Kamisago, M.; Sharma, S. D.; DePalma, S. R.; Solomon, S.; Sharma, P.; McDonough, B.; Smoot, L.; Mullen, M. P.; Woolf, P. K.; Wigle, E. D.; Seidman, J. G. und Seidman, C. E. (2000): Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy, N Engl J Med (343) [23], Seite 1688-96. [49] Saez, L. J.; Gianola, K. M.; McNally, E. M.; Feghali, R.; Eddy, R.; Shows, T. B. und Leinwand, L. A. (1987): Human cardiac myosin heavy chain genes and their linkage in the genome, Nucleic Acids Res (15) [13], Seite 5443-59. [50] Matsuoka, R.; Yoshida, M. C.; Kanda, N.; Kimura, M.; Ozasa, H. und Takao, A. (1989): Human cardiac myosin heavy chain gene mapped within chromosome region 14q11.2----q13, Am J Med Genet (32) [2], Seite 279-84. [51] Jaenicke, T.; Diederich, K. W.; Haas, W.; Schleich, J.; Lichter, P.; Pfordt, M.; Bach, A. und Vosberg, H. P. (1990): The complete sequence of the human beta-myosin heavy chain gene and a comparative analysis of its product, Genomics (8) [2], Seite 194-206. [52] Geisterfer-Lowrance, A. A.; Kass, S.; Tanigawa, G.; Vosberg, H. P.; McKenna, W.; Seidman, C. E. und Seidman, J. G. (1990): A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation, Cell (62) [5], Seite 999-1006. [53] Paré, J.A.P.; Fraser, R.G.; Pirozynski, W.J.; Shanks, J.A. und Stubington, D. (1961): Hereditary cardiovascular dysplasia: a form of familial cardiomyopathy, Am J Med (31), Seite 37-62. [54] Richard, P.; Charron, P.; Carrier, L.; Ledeuil, C.; Cheav, T.; Pichereau, C.; Benaiche, A.; Isnard, R.; Dubourg, O.; Burban, M.; Gueffet, J. P.; Millaire, A.; Desnos, M.; Schwartz, K.; Hainque, B. und Komajda, M. (2003): Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy, Circulation (107) [17], Seite 2227-32. [55] Bonne, G.; Carrier, L.; Richard, P.; Hainque, B. und Schwartz, K. (1998): Familial hypertrophic cardiomyopathy: from mutations to functional defects, Circ Res (83) [6], Seite 580-93. [56] Anderson, P. A.; Greig, A.; Mark, T. M.; Malouf, N. N.; Oakeley, A. E.; Ungerleider, R. M.; Allen, P. D. und Kay, B. K. (1995): Molecular basis of human cardiac troponin T isoforms expressed in the developing, adult, and failing heart, Circ Res (76) [4], Seite 681-6. [57] Mesnard, L.; Logeart, D.; Taviaux, S.; Diriong, S.; Mercadier, J. J. und Samson, F. (1995): Human cardiac troponin T: cloning and expression of new isoforms in the normal and failing heart, Circ Res (76) [4], Seite 687-92. [58] Zot, A. S. und Potter, J. D. (1987): Structural aspects of troponin-tropomyosin regulation of skeletal muscle contraction, Annu Rev Biophys Biophys Chem (16), Seite 535-59. [59] Townsend, P. J.; Farza, H.; MacGeoch, C.; Spurr, N. K.; Wade, R.; Gahlmann, R.; Yacoub, M. H. und Barton, P. J. (1994): Human cardiac troponin T: identification of fetal isoforms and assignment of the TNNT2 locus to chromosome 1q, Genomics (21) [2], Seite 311-6. [60] Jin, J. P.; Huang, Q. Q.; Yeh, H. I. und Lin, J. J. (1992): Complete nucleotide sequence and structural organization of rat cardiac troponin T gene. A single gene generates embryonic and adult isoforms via developmentally regulated alternative splicing, J Mol Biol (227) [4], Seite 1269-76. [61] Forissier, J. F.; Carrier, L.; Farza, H.; Bonne, G.; Bercovici, J.; Richard, P.; Hainque, B.; Townsend, P. J.; Yacoub, M. H.; Faure, S.; Dubourg, O.; Millaire, A.; Hagege, A. A.; Desnos, M.; Komajda, M. und Schwartz, K. (1996): Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy, Circulation (94) [12], Seite 3069-73. [62] Moolman, J. C.; Corfield, V. A.; Posen, B.; Ngumbela, K.; Seidman, C.; Brink, P. A. und Watkins, H. (1997): Sudden death due to troponin T mutations, J Am Coll Cardiol (29) [3], Seite 549-55. [63] Watkins, H.; Conner, D.; Thierfelder, L.; Jarcho, J. A.; MacRae, C.; McKenna, W. J.; Maron, B. J.; Seidman, J. G. und Seidman, C. E. (1995): Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy, Nat Genet (11) [4], Seite 434-7. [64] Daehmlow, S.; Erdmann, J.; Knueppel, T.; Gille, C.; Froemmel, C.; Hummel, M.; Hetzer, R. und Regitz-Zagrosek, V. (2002): Novel mutations in sarcomeric protein genes in dilated cardiomyopathy, Biochem Biophys Res Commun (298) [1], Seite 116-20. [65] Olson, T. M.; Kishimoto, N. Y.; Whitby, F. G. und Michels, V. V. (2001): Mutations that alter the surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy, J Mol Cell Cardiol (33) [4], Seite 723-32. [66] Kimura, A.; Harada, H.; Park, J. E.; Nishi, H.; Satoh, M.; Takahashi, M.; Hiroi, S.; Sasaoka, T.; Ohbuchi, N.; Nakamura, T.; Koyanagi, T.; Hwang, T. H.; Choo, J. A.; Chung, K. S.; Hasegawa, A.; Nagai, R.; Okazaki, O.; Nakamura, H.; Matsuzaki, M.; Sakamoto, T.; Toshima, H.; Koga, Y.; Imaizumi, T. und Sasazuki, T. (1997): Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy, Nat Genet (16) [4], Seite 379-82. [67] Murphy, R. T.; Mogensen, J.; Shaw, A.; Kubo, T.; Hughes, S. und McKenna, W. J. (2004): Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy, Lancet (363) [9406], Seite 371-2. [68] Hoffmann, B.; Schmidt-Traub, H.; Perrot, A.; Osterziel, K. J. und Gessner, R. (2001): First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy, Hum Mutat (17) [6], Seite 524. [69] Mogensen, J.; Murphy, R. T.; Shaw, T.; Bahl, A.; Redwood, C.; Watkins, H.; Burke, M.; Elliott, P. M. und McKenna, W. J. (2004): Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy, J Am Coll Cardiol (44) [10], Seite 2033-40. [70] Mogensen, J.; Klausen, I. C.; Pedersen, A. K.; Egeblad, H.; Bross, P.; Kruse, T. A.; Gregersen, N.; Hansen, P. S.; Baandrup, U. und Borglum, A. D. (1999): Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy, J Clin Invest (103) [10], Seite R39-43. [71] Poetter, K.; Jiang, H.; Hassanzadeh, S.; Master, S. R.; Chang, A.; Dalakas, M. C.; Rayment, I.; Sellers, J. R.; Fananapazir, L. und Epstein, N. D. (1996): Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle, Nat Genet (13) [1], Seite 63-9. [72] Gerull, B.; Gramlich, M.; Atherton, J.; McNabb, M.; Trombitas, K.; Sasse-Klaassen, S.; Seidman, J. G.; Seidman, C.; Granzier, H.; Labeit, S.; Frenneaux, M. und Thierfelder, L. (2002): Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy, Nat Genet (30) [2], Seite 201-4. [73] Knöll, R.; Hoshijima, M.; Hoffman, H. M.; Person, V.; Lorenzen-Schmidt, I.; Bang, M. L.; Hayashi, T.; Shiga, N.; Yasukawa, H.; Schaper, W.; McKenna, W.; Yokoyama, M.; Schork, N. J.; Omens, J. H.; McCulloch, A. D.; Kimura, A.; Gregorio, C. C.; Poller, W.; Schaper, J.; Schultheiss, H. P. und Chien, K. R. (2002): The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy, Cell (111) [7], Seite 943-55. [74] Arimura, T.; Hayashi, T.; Terada, H.; Lee, S. Y.; Zhou, Q.; Takahashi, M.; Ueda, K.; Nouchi, T.; Hohda, S.; Shibutani, M.; Hirose, M.; Chen, J.; Park, J. E.; Yasunami, M.; Hayashi, H. und Kimura, A. (2004): A Cypher/ZASP mutation associated with dilated cardiomyopathy alters the binding affinity to protein kinase C, J Biol Chem (279) [8], Seite 6746-52. [75] Olson, T. M.; Illenberger, S.; Kishimoto, N. Y.; Huttelmaier, S.; Keating, M. T. und Jockusch, B. M. (2002): Metavinculin mutations alter actin interaction in dilated cardiomyopathy, Circulation (105) [4], Seite 431-7. [76] Schmitt, J. P.; Kamisago, M.; Asahi, M.; Li, G. H.; Ahmad, F.; Mende, U.; Kranias, E. G.; MacLennan, D. H.; Seidman, J. G. und Seidman, C. E. (2003): Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban, Science (299) [5611], Seite 1410-3. [77] Bienengraeber, M.; Olson, T. M.; Selivanov, V. A.; Kathmann, E. C.; O'Cochlain, F.; Gao, F.; Karger, A. B.; Ballew, J. D.; Hodgson, D. M.; Zingman, L. V.; Pang, Y. P.; Alekseev, A. E. und Terzic, A. (2004): ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating, Nat Genet (36) [4], Seite 382-7. [78] Olson, T. M. und Keating, M. T. (1996): Mapping a cardiomyopathy locus to chromosome 3p22-p25, J Clin Invest (97) [2], Seite 528-32. [79] McNair, W. P.; Ku, L.; Taylor, M. R.; Fain, P. R.; Dao, D.; Wolfel, E. und Mestroni, L. (2004): SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia, Circulation (110) [15], Seite 2163-7. [80] Bione, S.; D'Adamo, P.; Maestrini, E.; Gedeon, A. K.; Bolhuis, P. A. und Toniolo, D. (1996): A novel X-linked gene, G4.5. is responsible for Barth syndrome, Nat Genet (12) [4], Seite 385-9. [81] Schönberger, J.; Wang, L.; Shin, J. T.; Kim, S. D.; Depreux, F. F.; Zhu, H.; Zon, L.; Pizard, A.; Kim, J. B.; Macrae, C. A.; Mungall, A. J.; Seidman, J. G. und Seidman, C. E. (2005): Mutation in the transcriptional coactivator EYA4 causes dilated cardiomyopathy and sensorineural hearing loss, Nat Genet (27), Seite 27 [82] Henry, W. L.; Gardin, J. M.; Ware, J. H.; Philips, A. V. und Cooper, T. A. (1980): Echocardiographic measurements in normal subjects from infancy to old age, Circulation (62) [5], Seite 1054-61. [83] Miller, S. A.; Dykes, D. D. und Polesky, H. F. (1988): A simple salting out procedure for extracting DNA from human nucleated cells, Nucleic Acids Res (16) [3], Seite 1215. [84] Mullis, K. B. und Faloona, F. A. (1987): Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction, Methods Enzymol (155), Seite 335-50. [85] Cheng, S.; Chang, S. Y.; Gravitt, P. und Respess, R. (1994): Long PCR, Nature (369) [6482], Seite 684-5. [86] Orita, M.; Iwahana, H.; Kanazawa, H.; Hayashi, K. und Sekiya, T. (1989): Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms, Proc Natl Acad Sci U S A (86) [8], Seite 2766-70. [87] Spinardi, L.; Mazars, R. und Theillet, C. (1991): Protocols for an improved detection of point mutations by SSCP, Nucleic Acids Res (19) [14], Seite 4009. [88] Condie, A.; Eeles, R.; Borresen, A. L.; Coles, C.; Cooper, C. und Prosser, J. (1993): Detection of point mutations in the p53 gene: comparison of single-strand conformation polymorphism, constant denaturant gel electrophoresis, and hydroxylamine and osmium tetroxide techniques, Hum Mutat (2) [1], Seite 58-66. [89] Glavac, D. und Dean, M. (1993): Optimization of the single-strand conformation polymorphism (SSCP) technique for detection of point mutations, Hum Mutat (2) [5], Seite 404-14. [90] Grompe, M. (1993): The rapid detection of unknown mutations in nucleic acids, Nat Genet (5) [2], Seite 111-7. [91] Hayashi, K. und Yandell, D. W. (1993): How sensitive is PCR-SSCP?, Hum Mutat (2) [5], Seite 338-46. [92] Sanger, F.; Nicklen, S. und Coulson, A. R. (1977): DNA sequencing with chain-terminating inhibitors, Proc Natl Acad Sci U S A (74) [12], Seite 5463-7. [93] Cooper, D. N. und Schmidtke, J. (1984): DNA restriction fragment length polymorphisms and heterozygosity in the human genome, Hum Genet (66) [1], Seite 1-16. [94] Max Heiman, Yale University New Haven, USA:: Webcutter 2.0. http://www.firstmarket.com/cutter/cut2.html [95] Nagamine, C. M.; Chan, K. und Lau, Y. F. (1989): A PCR artifact: generation of heteroduplexes, Am J Hum Genet (45) [2], Seite 337-9. [96] Dianzani, I.; Camaschella, C.; Ponzone, A. und Cotton, R. G. (1993): Dilemmas and progress in mutation detection, Trends Genet (9) [12], Seite 403-5. [97] den Dunnen, J. T. und Antonarakis, S. E. (2000): Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion, Hum Mutat (15) [1], Seite 7-12. [98] HGVS, Human Genome Variation Society:: Nomenclature for the description of sequence variations. http://www.genomic.unimelb.edu.au/mdi/mutnomen/". Stand: 4. März 2005. [99] Erdmann, J.; Daehmlow, S.; Wischke, S.; Senyuva, M.; Werner, U.; Raible, J.; Tanis, N.; Dyachenko, S.; Hummel, M.; Hetzer, R. und Regitz-Zagrosek, V. (2003): Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy, Clin Genet (64) [4], Seite 339-49. [100] Regitz-Zagrosek, V.; Erdmann, J.; Wellnhofer, E.; Raible, J. und Fleck, E. (2000): Novel mutation in the alpha-tropomyosin gene and transition from hypertrophic to hypocontractile dilated cardiomyopathy, Circulation (102) [17], Seite E112-6. [101] Hina, K.; Kusachi, S.; Iwasaki, K.; Nogami, K.; Moritani, H.; Kita, T.; Taniguchi, G. und Tsuji, T. (1993): Progression of left ventricular enlargement in patients with hypertrophic cardiomyopathy: incidence and prognostic value, Clin Cardiol (16) [5], Seite 403-7. [102] Raible, J.; Kallisch, H.; Erdmann, J. und Regitz-Zagrosek, V. (2001): Sensitivität und Spezifität von SSCP und Temperatur-modulierter Heteroduplexanalyse (TMHA) in der Diagnostik von Mutationen im b MHC-Gen, Z Kardiol (90, Supplement 2), Seite 323. [103] Highsmith, W. E., Jr.; Nataraj, A. J.; Jin, Q.; O'Connor, J. M.; El-Nabi, S. H.; Kusukawa, N. und Garner, M. M. (1999): Use of DNA toolbox for the characterization of mutation scanning methods. II: evaluation of single-strand conformation polymorphism analysis, Electrophoresis (20) [6], Seite 1195-203. [104] Epstein, N. D.; Cohn, G. M.; Cyran, F. und Fananapazir, L. (1992): Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu----Val mutation and a 403Arg----Gln mutation, Circulation (86) [2], Seite 345-52. [105] Philips, A. V. und Cooper, T. A. (2000): RNA processing and human disease, Cell Mol Life Sci (57) [2], Seite 235-49. [106] Krawczak, M.; Reiss, J. und Cooper, D. N. (1992): The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences, Hum Genet (90) [1-2], Seite 41-54. [107] Berkeley Drosophila Genome Project, Universitiy of California Berkeley, USA:: Splice Site Prediction. http://www.fruitfly.org/seq_tools/splice.html [108] Grantham, R.; Gautier, C.; Gouy, M.; Mercier, R. und Pave, A. (1980): Codon catalog usage and the genome hypothesis, Nucleic Acids Res (8) [1], Seite r49-r62. [109] Robinson, M.; Lilley, R.; Little, S.; Emtage, J. S.; Yarranton, G.; Stephens, P.; Millican, A.; Eaton, M. und Humphreys, G. (1984): Codon usage can affect efficiency of translation of genes in Escherichia coli, Nucleic Acids Res (12) [17], Seite 6663-71. [110] Bulmer, M. (1988): Codon usage and intragenic position, J Theor Biol (133) [1], Seite 67-71. [111] Kazusa DNA Research Institute, Japan:: Codon Usage Database. http://www.kazusa.or.jp/codon". Stand: 15. März 2005. [112] Zatkova, A.; Messiaen, L.; Vandenbroucke, I.; Wieser, R.; Fonatsch, C.; Krainer, A. R. und Wimmer, K. (2004): Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1, Hum Mutat (24) [6], Seite 491-501. [113] Lorson, C. L.; Hahnen, E.; Androphy, E. J. und Wirth, B. (1999): A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy, Proc Natl Acad Sci U S A (96) [11], Seite 6307-11. [114] Shimizu, M.; Ino, H.; Yasuda, T.; Fujino, N.; Uchiyama, K.; Mabuchi, T.; Konno, T.; Kaneda, T.; Fujita, T.; Masuta, E.; Katoh, M.; Funada, A. und Mabuchi, H. (2005): Gene mutations in adult Japanese patients with dilated cardiomyopathy, Circ J (69) [2], Seite 150-3. [115] Suzuki, M.; Carlson, K. M.; Marchuk, D. A. und Rockman, H. A. (2002): Genetic modifier loci affecting survival and cardiac function in murine dilated cardiomyopathy, Circulation (105) [15], Seite 1824-9. [116] Chien, K. R. (1999): Stress pathways and heart failure, Cell (98) [5], Seite 555-8. [117] Watkins, H.; Rosenzweig, A.; Hwang, D. S.; Levi, T.; McKenna, W.; Seidman, C. E. und Seidman, J. G. (1992): Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy, N Engl J Med (326) [17], Seite 1108-14. [118] Charron, P.; Dubourg, O.; Desnos, M.; Bennaceur, M.; Carrier, L.; Camproux, A. C.; Isnard, R.; Hagege, A.; Langlard, J. M.; Bonne, G.; Richard, P.; Hainque, B.; Bouhour, J. B.; Schwartz, K. und Komajda, M. (1998): Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene, Circulation (97) [22], Seite 2230-6. [119] Marian, A. J. und Roberts, R. (2001): The molecular genetic basis for hypertrophic cardiomyopathy, J Mol Cell Cardiol (33) [4], Seite 655-70. [120] Villard, E.; Duboscq-Bidot, L.; Charron, P.; Benaiche, A.; Conraads, V.; Sylvius, N. und Komajda, M. (2005): Mutation screening in dilated cardiomyopathy: prominent role of the beta myosin heavy chain gene, Eur Heart J (15), Seite 15 [121] Herskowitz, I. (1987): Functional inactivation of genes by dominant negative mutations, Nature (329) [6136], Seite 219-22. [122] Rayment, I.; Holden, H. M.; Sellers, J. R.; Fananapazir, L. und Epstein, N. D. (1995): Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy, Proc Natl Acad Sci U S A (92) [9], Seite 3864-8. [123] Geisterfer-Lowrance, A. A.; Christe, M.; Conner, D. A.; Ingwall, J. S.; Schoen, F. J.; Seidman, C. E. und Seidman, J. G. (1996): A mouse model of familial hypertrophic cardiomyopathy, Science (272) [5262], Seite 731-4. [124] Fatkin, D.; Christe, M. E.; Aristizabal, O.; McConnell, B. K.; Srinivasan, S.; Schoen, F. J.; Seidman, C. E.; Turnbull, D. H. und Seidman, J. G. (1999): Neonatal cardiomyopathy in mice homozygous for the Arg403Gln mutation in the alpha cardiac myosin heavy chain gene, J Clin Invest (103) [1], Seite 147-53. [125] McConnell, B. K.; Jones, K. A.; Fatkin, D.; Arroyo, L. H.; Lee, R. T.; Aristizabal, O.; Turnbull, D. H.; Georgakopoulos, D.; Kass, D.; Bond, M.; Niimura, H.; Schoen, F. J.; Conner, D.; Fischman, D. A.; Seidman, C. E. und Seidman, J. G. (1999): Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice, J Clin Invest (104) [9], Seite 1235-44. [126] Karkkainen, S.; Helio, T.; Jaaskelainen, P.; Miettinen, R.; Tuomainen, P.; Ylitalo, K.; Kaartinen, M.; Reissell, E.; Toivonen, L.; Nieminen, M. S.; Kuusisto, J.; Laakso, M. und Peuhkurinen, K. (2004): Two novel mutations in the beta-myosin heavy chain gene associated with dilated cardiomyopathy, Eur J Heart Fail (6) [7], Seite 861-8. [127] Li, D.; Czernuszewicz, G. Z.; Gonzalez, O.; Tapscott, T.; Karibe, A.; Durand, J. B.; Brugada, R.; Hill, R.; Gregoritch, J. M.; Anderson, J. L.; Quinones, M.; Bachinski, L. L. und Roberts, R. (2001): Novel cardiac troponin T mutation as a cause of familial dilated cardiomyopathy, Circulation (104) [18], Seite 2188-93. [128] Stefanelli, C. B.; Rosenthal, A.; Borisov, A. B.; Ensing, G. J. und Russell, M. W. (2004): Novel troponin T mutation in familial dilated cardiomyopathy with gender-dependant severity, Mol Genet Metab (83) [1-2], Seite 188-96. [129] Hanson, E. L.; Jakobs, P. M.; Keegan, H.; Coates, K.; Bousman, S.; Dienel, N. H.; Litt, M. und Hershberger, R. E. (2002): Cardiac troponin T lysine 210 deletion in a family with dilated cardiomyopathy, J Card Fail (8) [1], Seite 28-32. [130] Gille, C. und Frömmel, C. (2001): STRAP: editor for STRuctural Alignments of Proteins, Bioinformatics (17) [4], Seite 377-8. [131] Srikakulam, R. und Winkelmann, D. A. (1999): Myosin II folding is mediated by a molecular chaperonin, J Biol Chem (274) [38], Seite 27265-73. [132] Schönberger, J. und Seidman, C. E. (2001): Many roads lead to a broken heart: the genetics of dilated cardiomyopathy, Am J Hum Genet (69) [2], Seite 249-60. [133] Baig, M. K.; Goldman, J. H.; Caforio, A. L.; Coonar, A. S.; Keeling, P. J. und McKenna, W. J. (1998): Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease, J Am Coll Cardiol (31) [1], Seite 195-201. [134] Poole-Wilson, P. A.; Swedberg, K.; Cleland, J. G.; Di Lenarda, A.; Hanrath, P.; Komajda, M.; Lubsen, J.; Lutiger, B.; Metra, M.; Remme, W. J.; Torp-Pedersen, C.; Scherhag, A. und Skene, A. (2003): Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial, Lancet (362) [9377], Seite 7-13. [135] (1992): The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions., N Engl J Med (327) [10], Seite 685-91. [136] Waagstein, F.; Bristow, M. R.; Swedberg, K.; Camerini, F.; Fowler, M. B.; Silver, M. A.; Gilbert, E. M.; Johnson, M. R.; Goss, F. G. und Hjalmarson, A. (1993): Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group, Lancet (342) [8885], Seite 1441-6. [137] Hosenpud, J. D.; Bennett, L. E.; Keck, B. M.; Boucek, M. M. und Novick, R. J. (2000): The Registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000, J Heart Lung Transplant (19) [10], Seite 909-31.